作者
Tarik Asselah,Vladimir Chulanov,Pietro Lampertico,Heiner Wedemeyer,Adrian Streinu‐Cercel,Victor Pântea,Ştefan Lazăr,Gheorghe Plăcintă,George Sebastian Gherlan,Pavel Bogomolov,T.V. Stepanova,Viacheslav Morozov,V. Е. Syutkin,Olga Sagalova,Dmitry Manuilov,Renée-Claude Mercier,Lei Ye,Ben L. Da,Grace M. Chee,Audrey H. Lau,Anu Osinusi,Marc Bourlière,Vlad Ratziu,Stanislas Pol,Marie‐Noëlle Hilleret,Fabien Zoulim
摘要
In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy with bulevirtide and peginterferon alfa-2a, particularly with regard to finite treatment, is unclear.
cdercder
平常的毛豆
kento
余味
back you up
斯寜
爱静静
HEIKU
pluto
eee
MchemG
随遇而安
andrele
Li
夜白
归尘
竹筏过海
勤劳的忆寒
今天只做一件事
bc
皖公网安备34019202002308
